Methylation Regulation of TLR3 on Immune Parameters in Lung Adenocarcinoma

Frontiers in Oncology

Zhi Zhang¹  Qinqin Tian²  Ang Li²  Xuemei Zhang²  Yi Zhang³  Hongjiao Wu⁴ 

[1] Affiliated Tangshan Gongren Hospital, North China University of Science and Technology, Tangshan, China;College of Life Science, North China University of Science and Technology, Tangshan, China;School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China;School of Public Health, North China University of Science and Technology, Tangshan, China;

关键词: TLR3;    methylation;    lung adenocarcinoma;    immune infiltration;    apoptosis;   

DOI  :  10.3389/fonc.2021.620200

来源: DOAJ

【 摘 要 】

This study aims to analyze the methylation regulation of TLR3 in lung adenocarcinoma (LUAD) and to explore the association of TLR3 expression with immune microenvironment. TLR3 has a decreased expression in LUAD tissues and low expression of TLR3 is not only associated with poor prognosis in patients with LUAD, but also can be used as a diagnostic marker. Bisulfite sequencing PCR (BSP) results showed that the methylation level in the promoter of TLR3 was negatively correlated with the level of TLR3 mRNA in LUAD tissues. TIMER analysis showed that TLR3 was negatively correlated with the tumor purity of LUAD and positively with immune cell infiltration to some extent. ESTIMATE analysis also suggested that TLR3 expression and its methylation had significant correlation with immune score. The lower immune scores were associated with the late stage of LUAD and poor prognosis. The high expression of TLR3 might inhibit the development of LUAD by activating apoptosis pathway. The proteins interacted with TLR3 were mainly involved in the apoptosis pathway and positively correlated with the key genes (MYD88, Caspase 8, BIRC3, PIK3R1) in this pathway. Therefore, TLR3 as a key biomarker for prognosis and diagnosis in LUAD, might be considered as a potential epigenetic and immunotherapeutic target.

【 授权许可】

Unknown